p53-plus-ras-transformed rat cell lines express a tumor-specific transplantation antigen that is common to a number (85%) of independently derived p53-plus-ras-transformed cell lines. This has been shown by immunizing rats with irradiated p53-plus-ras-transformed cells and demonstrating protection of these animals by subsequent live-cell tumor challenge. Several c-myc-plus-ras-transformed cell lines (54% of the lines tested) and one adenovirus Ela-plus-ras-transformed cell line (9% of those tested) were shown to share a common tumor-specific transplantation antigen by their ability to immunize a rat against a p53-plus-ras cell line challenge. Several experimental approaches have been used to fractionate and identify the antigen common to these cell lines. The experimental results reported here make it clear that the p53 protein common to most of these transformed cell lines is not likely to be the tumor-specific transplantation antigen.
Hamsters that bear simian virus 40 (SV40)-induced tumors produce antibodies directed against the virus-encoded large and small tumor antigen (T antigen) (1) and the cellularly encoded gene product p53 (9) . Similarly, mice immunized with methylcholanthrene-induced tumor cells produce antibodies directed against p53 protein, which is expressed at high levels in these cells (4) . Indeed, anti-p53 antibodies have been detected in humans with several different types of cancers (3). For all of these reasons, p53 has been termed a tumor antigen. In the case of the SV40 large tumor antigen, it has also been shown to be a tumor-specific transplantation rejection antigen (TSTA) (13) . Immunizing animals with SV40 large T antigen can protect against subsequent challenges with live tumorigenic SV40-transformed cells (13) . Mutant genomic and cDNA clones of p53, when cotransfected into rat embryo fibroblasts (REFs) with the T24 ras oncogene, produce transformed cell foci (7, 8) . These foci are tumorigenic in immature syngeneic rats (6, 8) . These observations provided the opportunity to investigate (i) whether p53-plus-ras-transformed cells express a TSTA activity, (ii) whether such an activity was common to all p53-plus-ras-transformed cell lines or even other cell lines transformed by different oncogenes, and (iii) whether such a common TSTA activity, if present, was the p53 protein itself or another entity. The results of the experiments presented here demonstrate that (i) p53-plus-ras-transformed cell lines do express a TSTA activity, (ii) such an activity is common to most p53-plus-ras-transformed cell lines and even some myc-plus-ras-transformed cell lines, and (iii) this TSTA activity is most likely not the p53 protein itself.
MATERIALS AND METHODS
Vector construction and cell lines. All p53 expression vectors have been described previously (7, 8, 12 terminal repeat, have been described previously (10, 11) . The T24 ras gene construct has also been described previously (7, 8, 12) . Preparations of REFs, DNA transfections of these cells, and the cloning and isolation of foci have all been described previously (7, 8) . The properties of these cell lines have been characterized (7, 8 (7, 8) , a murine mutated cDNA-genomic hybrid clone under the control of the Harvey murine sarcoma virus long terminal repeat, by using the modified calcium phosphate procedure (7, 8) . The cells were transfected for 17 to 18 h, refed with Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum, and allowed to recover for an additional day before being passaged at a 1:3 dilution. Cells were refed at 4-to 5-day intervals. Morphologically distinct foci were visible 7 to 10 days after subculture, and selected foci were cloned and expanded into cell lines. All of these cell lines had a high saturation density and produced tumors in syngeneic animals (7, 8) .
Cell fractionation of TSTA activity. Localization of immunogenic activity in p53-plus-ras-transformed cell line B3 was performed as follows. Confluent monolayers of B3 cells were harvested by dislodging them with a gentle stream of cold PBS, and cells were collected by centrifugation. Cells were suspended in hypotonic buffer containing protease inhibitors and allowed to swell in ice for 20 min. Cells were then lysed by Dounce homogenization, and the cell debris and unbroken cells were removed by centrifugation at 500 x g for 10 min. Nuclei were then pelleted at 1,500 x g, and the postnuclear supernatant (which contained total cellular membrane vesicles) was recovered by centrifugation at 150,000 x g for 60 min. The resultant pellet of total cellular membranes was suspended by gentle homogenization in PBS and washed by centrifugation as described above. Total cellular membranes were suspended at a concentration of 1 to 2 mg/ml in 0.1 M sodium carbonate, pH 11.5, and incubated on ice for 30 min. Membranes were recovered by ultracentrifugation for 60 min at 100,000 x g and suspended in 0.1 M Tris hydrochloride, pH 7.5, containing protease inhibitors. The extracted fraction was neutralized by the addition of 3 M Tris hydrochloride, pH 7.5, and frozen in liquid nitrogen. The supernatant resulting from high-speed centrifugation of the total cellular homogenate was frozen in N2. Proteins contained in the nuclear fraction were extracted by stirring with 0.6 M NaCl for 30 min followed by centrifugation at 20,000 x g for 30 min. This supernatant contained extracted nuclear proteins and was frozen in liquid nitrogen.
After protein concentration determination, the different subcellular fractions (total cellular homogenate, nuclear extract, alkali-extracted total cellular membranes, and cytosolic proteins) were used for tumor protection studies. Pairs of Fisher rats were immunized twice at 7-day intervals with 200 p,g of protein from each fraction. Rats were then challenged with 2.5 x 103 B3 cells, and tumor development was monitored as previously described.
This experiment was repeated two times with pairs of rats and fresh extracts derived from different preparations of B3 cells. Rats received total cell homogenate, nuclear extract, total cell membranes, or cytosolic extract which had, in some cases, been purified over an anti-p53 immunoaffinity column (2). Material which was not retained on the affinity column (see Fig. 2 , lane b) and material specifically eluted from the affinity column (see Fig. 2 , lane c) were both used to inoculate rats (see Table 3 ).
RESULTS AND DISCUSSION The experiments described here were carried out to determine whether cell lines transformed by the oncogenes p53 plus ras (6-8, 10) expressed a TSTA, and, if so, to characterize the nature of this activity. To address these questions experimentally, a p53-plus-ras-transformed Fisher rat cell line, called B3 (8) , was characterized in some detail before it was adopted as a standard cell line in these studies. Inoculation of 105 B3 cells subcutaneously into a 5-week-old Fisher rat produced a palpable tumor (0.5 cm) in 10 to 14 days. The kinetics of tumor growth in rats are presented in Having quantified all of these variables and determined the parameters for the transplantation rejection assay, the next question could be answered. Do all p53-plus-ras-transformed cell lines share a common TSTA activity or are they unique in this respect? Thirteen independently derived p53-plus-ras-transformed REF cell lines (7, 8) One of the common features of many transformed cell lines is that the levels of p53 protein are elevated in most cases because of the enhanced stability of the protein (7, 8) . Thus, p53 protein itself might be a reasonable candidate for the TSTA activity detected in the transformed REF cells. To test this idea, B3 cell extracts were fractionated after cell lysis. Differential centrifugation was used to obtain fractions rich in nuclei, total cellular membranes, or a soluble cytosolic component. Both the membrane fraction and the cytosolic or soluble fraction could confer protection from a B3 cell tumor challenge upon rats immunized with these fractions (Table 3) . Nuclear fractions failed to confer such protection (Table 3) . Extraction of the membrane fractions at alkaline pH (11.5) removes most of the proteins that are attached to membranes but are not integral membrane proteins. Treatment of this membrane fraction with alkali failed to remove the TSTA activity conferred upon rats by these B3 cell membranes. This observation suggests that at least one TSTA activity is due to an integral membrane protein.
Western blotting with p53 antibodies that recognize native and denatured p53 protein (8) failed to detect any p53 protein in this alkaline-treated membrane fraction that contained TSTA activity. The total cell homogenate cytosolic soluble proteins contained some TSTA activity (Table 3) and also were shown to contain large levels of p53 protein by Western blot analysis (Fig. 2, lane a) . The p53 protein in this fraction could be removed by passing these soluble proteins through a p53 antibody immunoaffinity column, which removed all of the detectable p53 protein in this preparation (Fig. 2, lane b) . This cytosolic fraction without detectable p53 retained its ability to protect rats from the B3 cell challenge (Table 3) . Finally, p53 was purified by immunoaffinity chromatography, as described previously (13) , from several sources: (i) Escherichia coli expressing a p53 cDNA clone (13), (ii) B3 cells, and (iii) Al cells (8 Adsorption of p53 from B3 soluble protein extracts. B3 cells were fractionated by hypotonic lysis as described in Materials and Methods. Soluble proteins were fractionated by DEAE chromatography, and the flowthrough fraction (which contained p53 and the TSTA activity) was recirculated over an immunoaffinity resin containing anti-p53 monoclonal antibody PAb421 as described previously (2) . The adsorbed and nonadsorbed fractions were used for immunization of rats as described in Materials and Methods. Animals were challenged with 2.5 x 103 B3 cells, and tumor production was monitored. An immunoblot of column fractions analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed as described previously (8) and is shown here. Lanes a, p53 immunoreactive protein in soluble extract; b, material not adsorbed by the anti-p53 antibody resin; c, p53 protein eluted from the immunoaffinity resin after elution of bound hsc70 with ATP as described previously (2) . +, TSTA activity; -, no TSTA activity. The immunizing dose of protein not adsorbed by the affinity resin was similar to that used in experiments with crude subcellular fractions or partially purified proteins (0.1 to 0.2 mg).
B3 cell line, there may be two different entities that demonstrate TSTA activity in rats. One of these appears to be an integral membrane protein, while the second one (related or not) fractionates with the soluble proteins from the cytosolic compartment. Thus, it appears that p53, the tumor antigen expressed at high levels and which is common in all of these transformed cell lines, does not have the ability to confer TSTA activity and protect rats from the B3 cell tumor challenge.
